TE
Terns Pharmaceuticals, Inc.
TERN · NASDAQ
$52.95 -0.04% (-$0.02)
Market Cap $4.77B
P/E Ratio -
Div. Yield -
ROE 29.95%
Bulios Fair Price
$47.43
10.4% downside
Current Price
$52.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TERN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 16.79x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 54.99%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 37.93%
ROE 29.95%
ROA 31.31%
Debt
90 /100
Low Debt/Equity 0.00x
Current ratio 19.52x
Net debt/EBITDA 1.47x
Stability
51 /100
Moderate Beta -0.38x
EPS volatility 25.05%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TERN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amy L. Burroughs
Employees
59
Headquarters
Foster City